Search

Your search keyword '"Jupimai, Thidarat"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Jupimai, Thidarat" Remove constraint Author: "Jupimai, Thidarat"
47 results on '"Jupimai, Thidarat"'

Search Results

1. Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms

3. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

6. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

7. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

8. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria

9. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

11. Going off antiretroviral treatment in a closely monitored HIV 'cure' trial: longitudinal assessments of acutely diagnosed trial participants and decliners

12. Lived experiences with pre-exposure prophylaxis uptake and adherence among transgender women in Thailand: a qualitative study.

15. Corrigendum to ‘Decision making for invasive and non-invasive optional procedures within an acute HIV research cohort in Bangkok,’ [Contemporary Clinical Trials Communication (2023)101054]

16. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

17. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

18. The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV‐Remission Trials.

19. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.

20. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features

21. Decision Making for Invasive and Non-Invasive Optional Procedures Within an Acute HIV Research Cohort in Bangkok

22. Recommendations from Thai stakeholders about protecting HIV remission (‘cure’) trial participants: report from a participatory workshop

23. Adaptation of a theory-based social networking and gamified app-based intervention to improve PrEP adherence among young men who have sex with men in Bangkok, Thailand (Preprint)

24. Adaptation of a Theory-Based Social Networking and Gamified App-Based Intervention to Improve Pre-Exposure Prophylaxis Adherence Among Young Men Who Have Sex With Men in Bangkok, Thailand: Qualitative Study (Preprint)

29. Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus.

30. Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV

31. Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV.

32. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine—a Staccato trial substudy

33. No change in calculated creatinine clearance after tenofovir initiation among Thai patients

34. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment

35. Behavioral and Emotional Problems in Thai Children With HIV Infection Compared to Children With and Without Other Chronic Diseases

36. Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure

38. Absence of Resistance Mutations in Antiretroviral-Naive Patients Treated with Ritonavir-Boosted Saquinavir

39. Adaptation of a Theory-Based Social Networking and Gamified App-Based Intervention to Improve Pre-Exposure Prophylaxis Adherence Among Young Men Who Have Sex With Men in Bangkok, Thailand: Qualitative Study.

40. Long-Term Efficacy and Safety of First-Line Therapy with Once-Daily Saquinavir/Ritonavir

41. Absence of Resistance Mutations in Antiretroviral-Naive Patients Treated with Ritonavir-Boosted Saquinavir

42. A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients

43. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine—a Staccato trial substudy

44. No change in calculated creatinine clearance after tenofovir initiation among Thai patients

45. Decision making for invasive and non-invasive optional procedures within an acute HIV research cohort in Bangkok.

46. Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV.

47. Reduced Time to Suppression Among Neonates With HIV Initiating Antiretroviral Therapy Within 7 Days After Birth.

Catalog

Books, media, physical & digital resources